BridgeBio Pharma, Inc. - Common Stock (BBIO) stock analysis
BBIO · BridgeBio Pharma, Inc. - Common Stock
Latest recorded price: USD 77.36
Sector and industry: Healthcare · Biotechnology
Fiscal 2025 figures: revenue growth 86.3%, free cash flow margin -89.0%. The model flags 2 risk signals for this company (1 high severity).
Similar companies in Healthcare
- Beam Therapeutics Inc. - Common Stock (BEAM)
- BioMarin Pharmaceutical Inc. - Common Stock (BMRN)
- Celldex Therapeutics, Inc. (CLDX)
- Corcept Therapeutics Incorporated - Common Stock (CORT)
- CRISPR Therapeutics AG - Common Shares (CRSP)
- Cytokinetics, Incorporated (CYTK)
- Denali Therapeutics Inc. - Common Stock (DNLI)
- Dianthus Therapeutics, Inc. (DNTH)